All In Biotech

Drug Trial Radar · NCT06782373

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

PAXIS: A Phase 2a and 2b Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Pacritinib in Patients With VEXAS Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

May 28, 2025

Primary completion

Oct 30, 2028

Study completion May 22, 2030

Sponsor

Lead sponsor
Swedish Orphan BiovitrumIndustry
Sponsor type
Industry
Collaborators
PSI CRO
First posted
Jan 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. In phase 2a, approximately 78 participants will be randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. In Phase 2b, approximately 78 participants will be randomized. Phase 2b participants will initially be randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. After dose selection, Phase 2b further participants will be randomized to either the selected pacritinib dose or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.

Conditions

  • VEXAS
  • VEXAS Syndrome

Interventions

  • PacritinibDrug

    Supplied in hard capsules.

  • PlaceboDrug

    Supplied in hard capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR), defined as achieving Partial Clinical Response or better at any time during the double-blind treatment period.Time frame: up to End of Week 24

Locations

39 sites in 8 countries. Site status is shown where the registry gives one.

  • Sobi Investigative Site

    Scottsdale, Arizona · Active not recruiting

  • Sobi Investigative Site

    Boston, Massachusetts · Active not recruiting

  • Sobi Investigative Site

    Rochester, Minnesota · Recruiting

  • Sobi Investigative Site

    New York, New York · Active not recruiting

  • Sobi Investigative Site

    Cleveland, Ohio · Active not recruiting

  • Sobi Investigative Site

    Columbus, Ohio · Active not recruiting

  • Sobi Investigative Site

    Houston, Texas · Active not recruiting

  • Sobi Investigative Site

    Salt Lake City, Utah · Active not recruiting

  • Sobi Investigative Site

    Seattle, Washington · Active not recruiting

  • Sobi Investigative Site

    Vancouver, British Columbia, Canada · Recruiting

  • Sobi Investigative Site

    Halifax, Nova Scotia, Canada · Recruiting

  • Sobi Investigative Site

    Toronto, Ontario, Canada · Recruiting

  • Sobi Investigative Site

    Montreal, Quebec, Canada · Active not recruiting

  • Sobi Investigative Site

    Lille, France · Active not recruiting

  • Sobi Investigative Site

    Paris, France · Active not recruiting

  • Sobi Investigative Site

    Paris, France · Active not recruiting

  • Sobi Investigative Site

    Pierre-Bénite, France · Active not recruiting

  • Sobi Investigative Site

    Poitiers, France · Active not recruiting

  • Sobi Investigative Site

    Toulouse, France · Active not recruiting

  • Sobi Investigative Site

    Tübingen, Baden-Wurttemberg, Germany · Active not recruiting

  • Sobi Investigative Site

    Munich, Bavaria, Germany · Active not recruiting

  • Sobi Investigative Site

    Hamburg, Free and Hanseatic City of Hamburg, Germany · Active not recruiting

  • Sobi Investigative Site

    Düsseldorf, North Rhine-Westphalia, Germany · Active not recruiting

  • Sobi Investigative Site

    Dresden, Saxony, Germany · Active not recruiting

  • Sobi Investigative Site

    Lübeck, Schleswig-Holstein, Germany · Active not recruiting

  • Sobi Investigative Site

    Milan, Italy · Active not recruiting

  • Sobi Investigative Site

    Padova, Italy · Active not recruiting

  • Sobi Investigative Site

    Reggio Emilia, Italy · Active not recruiting

  • Sobi Investigative Site

    Roma, Italy · Active not recruiting

  • Sobi Investigative Site

    Fukushima, Japan · Active not recruiting

  • Sobi Investigative Site

    Nagasaki, Japan · Active not recruiting

  • Sobi Investigative Site

    Yokohama, Japan · Active not recruiting

  • Sobi Investigative Site

    Barcelona, Spain · Active not recruiting

  • Sobi Investigative Site

    L'Hospitalet de Llobregat, Spain · Active not recruiting

  • Sobi Investigative Site

    Salamanca, Spain · Active not recruiting

  • Sobi Investigative Site

    Leeds, United Kingdom · Active not recruiting

  • Sobi Investigative Site

    London, United Kingdom · Active not recruiting

  • Sobi Investigative Site

    London, United Kingdom · Recruiting

  • Sobi Investigative Site

    Oxford, United Kingdom · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.